Earnings Calls In Brief
This article was originally published in The Gray Sheet
Executive Summary
Abbott's Xience V stent marks steady share gains: Abbott's Xience V everolimus-eluting coronary stent is "on track to exit 2007 with overall market share in the mid- to high-20% range" outside the United States, the firm reports during its July 18 earnings call. In India, market share is over 30%. The device debuted internationally last October and Abbott continues to expect U.S. approval in the first half of 2008; the firm completed its PMA filing in late May. Abbott's drug-eluting stent franchise generated $60 million in sales in Q2. The latter figure is roughly equal to the first quarter level because a 40% sequential increase in Xience sales was offset by lower "third party-related DES revenues," the firm explains. Overall Abbott Vascular sales, including stents, were up 63% year-over-year to $423 million in Q2 - reflecting Abbott's acquisition of Xience developer Guidant Vascular in April 2006. Leading a 20% advance in Abbott's medical product sales for the quarter, the Vascular segment remains on target for 60% growth for the full year, Abbott notes...
You may also be interested in...
Cordis Consolidation Will Help J&J Save $1.6 Billion In 2008
Flagging sales of Johnson & Johnson subsidiary Cordis' Cypher drug-eluting stent will require consolidation of the business and layoffs to help ensure sustained profitable growth, J&J says
Cordis Consolidation Will Help J&J Save $1.6 Billion In 2008
Flagging sales of Johnson & Johnson subsidiary Cordis' Cypher drug-eluting stent will require consolidation of the business and layoffs to help ensure sustained profitable growth, J&J says
Medtronic Preps For Upcoming FDA Panel Meetings On Stent, Spinal Disc
Medtronic is preparing for FDA panel reviews of its Bryan cervical spinal disc in July and itsEndeavor stent this fall, the firm announced May 22